X4 PHARMACEUTICALS, INC Accrued Liabilities, Current
X4 PHARMACEUTICALS, INC (XFOR) had Accrued Liabilities, Current of $14.13 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $14.13M.
- 2026-03-31: Accrued Liabilities, Current $17.05M.
- 2025-12-31: Accrued Liabilities, Current $18.60M.
- 2025-09-30: Accrued Liabilities, Current $16.66M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $14.13M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $17.05M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $18.60M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $16.66M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $13.06M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $12.61M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $23.00M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $19.46M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $19.74M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $13.47M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $12.82M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $16.18M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $15.23M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $11.76M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $12.03M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $9.13M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $8.58M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $6.88M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $7.87M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $9.07M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $9.61M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $10.71M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $8.02M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $8.53M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $8.00M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $5.79M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $6.46M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $5.70M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $5.09M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $4.18M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $3.25M 10-K · filed 2020-03-12 | $4.12M 10-K · filed 2019-03-11 |
| 2018-09-30 | $3.09M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $3.88M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $5.14M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $5.78M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |